22 completed, 14 recruiting, 9 unknown, 6 terminated. 29 Phase 2, 19 Phase 1, 5 Phase 3, 3 Not applicable, 1 Phase 4.
Follow CLL: new trials by email Literature Review of CLL trials Research Report on CLL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI Epcoritamab - CLL, CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Not yet recruiting | University of California, Irvine | 24 | 2026-10-01 | 2026-09-14 |
| ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL Rocbrutinib, Pirtobrutinib - CLL / SLL, CLL (Chronic Lymphocytic Leukemia) | Phase 3 | Recruiting | Newave Pharmaceutical Inc | 306 | 2026-04-23 | 2026-08-11 |
| Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma BAFF-R CAR-T - DLBCL, CLL | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-11-29 | 2026-05-13 |
| Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL AntiCD19 CAR-T combined with BTKi in the treatment of newly diagnosed high-risk CLL/SLL patients - CLL, CAR-T Cell Therapy | Not applicable | Recruiting | The Affiliated Hospital of Xuzhou Medical University | 50 | 2025-09-01 | 2025-08-13 |
| Study of Epcoritamab as a Consolidation Therapy in CLL/SLL Epcoritamab - CLL/SLL, CLL | Phase 2 | Recruiting | Zulfa Omer | 22 | 2025-08-22 | 2026-01-06 |
| A Phase I Dose Finding Study of MB-CART2219.1 CAR-T cells targeting CD19 and CD22 - Lymphoma, CLL | Phase 1 | Recruiting | University Hospital Tuebingen | 36 | 2025-06-23 | 2025-08-07 |
| A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors Tacabrutideg, Bendamustine, Idelalisib - CLL, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | BeOne Medicines | 250 | 2025-04-10 | 2026-09-28 |
| A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. Sonrotoclax, Zanubrutinib - Chronic Lymphocytic Leukemia, CLL | Phase 1 / Phase 2 | Recruiting | BeOne Medicines | 258 | 2025-01-23 | 2026-10-26 |
| Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia Myeloma, Lymphoma | Active not recruiting | Tel-Aviv Sourasky Medical Center | 250 | 2025-01-20 | 2025-07-28 | |
| The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China BTK inhibitor - CLL | Not yet recruiting | Peking University People's Hospital | 1000 | 2024-09-01 | 2024-08-21 | |
| The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China Zanubrutinib - CLL | Unknown | Peking University People's Hospital | 490 | 2024-08-01 | 2024-07-05 | |
| Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms Zinc-64 Aspartate - CLL, Solid Tumor, Adult | Phase 1 / Phase 2 | Recruiting | Vector Vitale LLC | 36 | 2024-05-15 | 2026-08-05 |
| Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia CARCIK-CD19 - B-cell NHL, CLL | Phase 1 / Phase 2 | Recruiting | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | 29 | 2023-12-01 | 2024-05-03 |
| Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) Sonrotoclax, Zanubrutinib, Venetoclax - CLL | Phase 3 | Active not recruiting | BeOne Medicines | 652 | 2023-11-11 | 2026-10-14 |
| A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). Nemtabrutinib, Venetoclax, Rituximab - Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 735 | 2023-08-08 | 2026-10-15 |
| Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL Zandelisib, Rituximab, Venetoclax - CLL | Phase 2 | Withdrawn | MEI Pharma, Inc. | 2022-11-22 | 2023-03-16 | |
| Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO) Calquence - CLL | Completed | iOMEDICO AG | 45 | 2022-10-12 | 2026-05-01 | |
| Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia, CLL | Recruiting | University Hospital, Clermont-Ferrand | 50 | 2022-03-07 | 2024-01-09 | |
| Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients Peripheral blood samples withdrawal - CLL, Chronic Lymphocytic Leukemia | Not applicable | Unknown | Gruppo Italiano Malattie EMatologiche dell'Adulto | 23 | 2021-10-01 | 2022-01-04 |
| A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. GB261 - B Cell NHL, CLL | Phase 1 / Phase 2 | Unknown | Genor Biopharma Co., Ltd. | 460 | 2021-08-31 | 2023-05-22 |
Showing 20 of 60. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (29) · Leukemia (10) · Neoplasms (7) · Hodgkin Disease (6) · Lymphoma (6) · Multiple Myeloma (6) · Recurrence (5) · Hematologic Neoplasms (4) · Leukemia, B-Cell (4) · Lymphoma, Follicular (4) · Lymphoma, Non-Hodgkin (4) · Lymphoma, Mantle-Cell (3) · Anemia, Aplastic (2) · Breast Neoplasms (2) · Chromosome 17 deletion (2)
Hemic and Lymphatic Diseases (41) · Neoplasms by Histologic Type (40) · Immune System Diseases (39) · Immunoproliferative Disorders (39) · Lymphatic Diseases (39) · Lymphoproliferative Disorders (39) · Hematologic Diseases (38) · Neoplasms (35) · Leukemia, Lymphoid (31) · Pathologic Processes (31) · Pathological Conditions, Signs and Symptoms (31) · Chronic Disease (30) · Disease Attributes (30) · Leukemia, B-Cell (26) · Leukemia (24)
Rituximab (7) · venetoclax (7) · Lenalidomide (6) · Bendamustine Hydrochloride (3) · Cyclophosphamide (3) · Cyclosporine (3) · acalabrutinib (3) · fludarabine (3) · obinutuzumab (3) · zanubrutinib (3) · Alemtuzumab (2) · Granulocyte Colony-Stimulating Factor (2) · Methylprednisolone (2) · Mycophenolic Acid (2) · Whole-Body Irradiation (2)
BeOne Medicines (3) · M.D. Anderson Cancer Center (3) · University of California, San Diego (3) · Beth Israel Deaconess Medical Center (2) · Gruppo Italiano Malattie EMatologiche dell'Adulto (2) · Peking University People's Hospital (2) · Tel-Aviv Sourasky Medical Center (2) · University of California, Irvine (2) · Acerta Pharma BV (1) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · Assuta Medical Center (1) · Bnai Zion Medical Center (1) · Carevive Systems, Inc. (1) · Centre Hospitalier Universitaire de Nice (1) · Chronic Lymphocytic Leukemia Research Consortium (1)
United States (33) · Germany (7) · Israel (6) · Italy (6) · Australia (5) · China (5) · France (5) · Netherlands (5) · United Kingdom (5) · Brazil (4) · Sweden (4) · Argentina (3) · Canada (3) · Denmark (3) · Japan (3)
David E Avigan, MD (2) · David F McDermott, MD (2) · Thomas J Kipps, MD, PhD (2) · Alessandra Ferrajoli, M.D. (1) · Andrea Biondi, MD (1) · Anthony Mato, MD (1) · Arnon Kater, PhD (1) · Bertil Uggla, Md, PhD (1) · Carsten U Niemann, MD, PhD (1) · Catherine C Coombs, MD (1) · Danelle F James, M.D. (1) · Dolores Grosso, DNP, CRNP (1) · Elizabeth Brem, MD (1)
PMID 16186597, PMID 21173095, PMID 21725050, PMID 23801633, PMID 26389849, PMID 29358183, PMID 30322319, PMID 33861303, PMID 34387648, PMID 35538512, PMID 37358640, PMID 37497921, PMID 38393694, PMID 40045895, PMID 40073834, PMID 41338862
2019 (1)